Using gradual escalation of TKI in cell culture media, these models are able to recapitulate molecular mechanisms of drug resistance observed in the clinic, including alteration of the drug target BCR::ABL1, perturbed expression of cell membrane transporters, downregulation of apoptosis, and activation of alternate cancer drivers. The gene discussed is BCR; the disease is cancer.